Screener
Vertex Pharmaceuticals VRTX JOURNAVX — Product revenues, net
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Vertex Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Vertex Pharmaceuticals’s 8-K, filed August 3, 2026. Open the filing →
- Filed
- Aug 3, 2026, 4:09 PM EDT
- Accession
- 0000875320-26-000256
FAQ
- What is Vertex Pharmaceuticals's JOURNAVX — product revenues, net?
- Vertex Pharmaceuticals (VRTX) reported JOURNAVX — product revenues, net of $49.6M in Q2 2026.
- How has Vertex Pharmaceuticals's JOURNAVX — product revenues, net changed year-over-year?
- Vertex Pharmaceuticals's JOURNAVX — product revenues, net increased by 313.3% year-over-year, from $12M to $49.6M.
- What does JOURNAVX — product revenues, net mean?
- This metric represents the total net sales generated from the JOURNAVX product line after accounting for returns, rebates, and other sales deductions. It serves as a key indicator of the commercial adoption and market penetration of this specific therapeutic asset within the company's portfolio. Tracking this revenue stream allows investors to assess the growth trajectory and financial contribution of the asset as it scales in the market.
Ask your AI about Vertex Pharmaceuticals's journavx — product revenues, net.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude